Symbiotec Pharmalab Limited
ListedMainboardHealthcare · NSE / BSE
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company that develops and manufactures active pharmaceutical ingredients, nutritional ingredients, and specialty products for both domestic and international markets. The company focuses on research-based manufacturing, strong quality standards, and sustainable processes, serving industries like pharmaceuticals, nutraceuticals, and wellness with high-quality and innovative products. With over 30 years of experience, it has grown from a small lab-scale steroid API manufacturer into a large, fully integrated company with approvals from global authorities like the US FDA, EU-GMP, and Korea’s Ministry of Food and Drug Safety. As of June 30, 2025, the company operates two large-scale manufacturing facilities with a chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
Price Band
₹938 – ₹988
Issue Size
₹1778.64 L Cr
Lot Size
15 shares
GMP
₹185
+18.7%
Est. Listing
₹1173
at current GMP
Subscribed
75.06x
overall
Open
24 Aug 2026
Close
27 Aug 2026
Allotment
28 Aug 2026
Refund
29 Aug 2026
Demat Credit
30 Aug 2026
Listing
1 Sep 2026
Last updated 27 days ago
Overall Subscription
75.06x
Total Demand
QIB Multiplier
181.20x
Institutions & Funds
NII / HNI
77.56x
High Net-Worth
Retail (RII)
13.65x
Individual Bidders
Category-Wise Subscription Breakup
Live bidding breakdown by institutional, non-institutional, and retail investors
| Category | Shares Offered | Shares Applied / Bid | Times Subscribed |
|---|---|---|---|
| QIB | 3,550,608 | 643,359,195 | 181.20x |
| NIB | 2,662,955 | 206,535,120 | 77.56x |
| HNIs(10L +) | 1,775,303 | 155,046,495 | 87.34x |
| HNIs (2-10L) | 887,652 | 51,488,625 | 58.01x |
| RETAIL | 6,213,562 | 84,810,630 | 13.65x |
| EMPLOYEES | 33,408 | 545,055 | 16.32x |
| Total | 15,123,488 | 1,141,785,120 | 75.06x |
Application-Wise Breakup
Total unique applications received across retail and HNI tranches
| Category | Applications Reserved | Applications Received | Times Subscribed |
|---|---|---|---|
| RETAIL | 414,237 | 4,846,619 | 11.70x |
| EMPLOYEES | — | 23,445 | 0.00x |
| HNIs(10L +) | 8,454 | 150,254 | 17.77x |
| HNIs (2-10L) | 4,277 | 237,513 | 55.53x |
| Total Applications | 426,968 | 5,257,831 | 12.31x |
Day-Wise Subscription Progress
About Symbiotec Pharmalab Limited Public Issue & Market Profile
Symbiotec Pharmalab Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹1,77,86,442 Crores. The shares are offered at a price band of ₹938 to ₹988 per equity share on NSE and BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
Bidding & Quota Instructions:
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Allotment Reconciliation Schedule:
Following the close of bidding on 2026-08-27, the basis of allotment is scheduled to be finalized on 2026-08-28. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Link Intime India Private Limited) or the BSE allotment checking window.
Frequently Asked Questions
What is the issue size and price band for Symbiotec Pharmalab Limited IPO?
The Symbiotec Pharmalab Limited IPO aggregate issue size is ₹1,77,86,442 Crores with an equity price band set at ₹938 to ₹988 per equity share. The retail lot size is 15 shares requiring a minimum capital outlay of approx. ₹14,820.
How can I check Symbiotec Pharmalab Limited IPO live subscription demand?
Live subscription figures are compiled real-time from the NSE and BSE bidding engines. You can track QIB, NII/HNI, and Retail category multiples directly on our dedicated live subscription page.
Where will Symbiotec Pharmalab Limited IPO allotment status be published?
The basis of allotment will be published on the official registrar portal (Link Intime India Private Limited) and the BSE status verification website on or around 2026-08-28.